The global Cancer Immunotherapy Market was valued at USD 153.3 billion in 2025 and is projected to grow from USD 166.4 billion in 2026 to USD 305.8 billion by 2033, registering a CAGR of 9.0% from 2026 to 2033. North America dominated the global market with the largest revenue share of 43.3% in 2025, primarily driven by the increasing prevalence of cancer, continuous innovation in...
The global Keytruda Market was valued at USD 31.4 billion in 2025 and is projected to grow from USD 32.7 billion in 2026 to USD 25.0 billion by 2033, registering a CAGR of -3.8% from 2026 to 2033. While Keytruda (pembrolizumab) remains one of the most successful immunotherapy drugs globally, the market is expected to face headwinds over the forecast period due to patent expiration,...
The demand within the Cancer Immunotherapy Market shows unique regional variations, with North America and Europe currently leading due to high research expenditure and robust insurance systems. However, emerging economies are quickly catching up as governments launch initiatives to improve cancer survival rates and foster local biopharmaceutical innovation. This global expansion is creating a...
The trajectory of the India Cancer Immunotherapy Market demonstrates a clear trend toward high-precision treatments. Immunotherapy, encompassing checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies, is rapidly gaining ground. This progress is fueled by a combination of academic research excellence and commercial agility, allowing India to stay competitive on the global...
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek